17:02 , May 23, 2019 |  BC Extra  |  Financial News

How Bicycle, Ideaya fared in debuts as they join 2019’s growing IPO class

A pair of newly listed biotechs trended in opposite directions during first-day trading Thursday. Bicycle slipped 14% after pricing its IPO at the bottom end of its proposed range, while Ideaya was up 12% after...
02:16 , Apr 5, 2019 |  BC Innovations  |  Targets & Mechanisms

Breaking up Hippo to tame proliferation

Drug developers are creating a new class of compounds that disrupt a protein-protein interaction in the Hippo pathway that goes awry in cancers and fibrotic diseases. At least two programs are poised to enter the...
17:49 , Mar 13, 2018 |  BC Innovations  |  Distillery Techniques

Disease models

TECHNOLOGY: Transgenics and knockouts BAP1-knockout, transgenic mice with melanocyte-specific expression of mutant human GNA11 could be used to screen therapies for metastatic uveal melanoma. Mice with systemic BAP1 knockout and tamoxifen-induced expression of the human...
21:06 , Nov 16, 2017 |  BC Innovations  |  Emerging Company Profile

YAP off, YAP on

Vivace Therapeutics Inc. exploits opposite angles of the Hippo-YAP pathway, with first-in-class inhibitors that turn it off in cancers with activating mutations and activators that turn it on to enhance tumor immunogenicity in other cancers....
17:44 , Nov 15, 2016 |  BC Innovations  |  Distillery Techniques

Chemistry

TECHNOLOGY: Tool compounds Aripiprazole-based biased agonists at the dopamine D2 receptor that activate GNAI1 but not arrestin beta 2 (ARRB2) could be useful as probes for D2 receptor-induced GNAI1 signaling in psychiatric and neurodegenerative diseases....
07:00 , Apr 7, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: G protein subunit α 11 (GNA11); uncoupling protein 1 mitochondrial proton carrier (UCP1)

Endocrine/metabolic disease INDICATION: Obesity Patient sample and cell culture studies suggest inhibiting GNA11 could help treat obesity. In white adipocytes from obesity patients, high levels of GNA11 correlated with low levels of UCP1 , a...
08:00 , Feb 12, 2009 |  BC Innovations  |  Targets & Mechanisms

New shock treatment

German researchers have found that targeting two G proteins could treat the vascular symptoms of anaphylactic shock while avoiding the cardiovascular side effects of epinephrine, the standard of care. If a selective inhibitor for the...
08:00 , Feb 5, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Inflammation

This week in therapeutics Indication Target/ marker/ pathway Summary Licensing status Publication and contact information Inflammation Anaphylaxis Guanine nucleotide-binding protein (G protein) a11 (Gq class) (GNA11); G protein q polypeptide (GNAQ; Gaq) Studies in mice...